A search of the English and French Literature from 1980 or 1997 identified
20 papers (excluding isolated cases reports) on the treatment of adult vari
cella. Most of these studies are ancient with an insufficient methodology.
Only 7 are randomized and only 6, open labeled or retrospective, include mo
re than 10 patients. Three studies compare acyclovir versus placebo in 316
immunocompetent adults with uncomplicated varicella, Only one has a correct
methodology. Acyclovir showed a benefit on all studied parameters only for
patients treated in the 24 h following eruption. One study randomised sori
vudine versus placebo in 186 patients. A reduction of duration of fever and
hospitalization was noted in patients receiving sovirudine. However, frequ
ency or duration of symptoms was only decreased in patients treated in the
24 h following eruption. Two studies evaluating open label acyclovir displa
yed a benefit only for early therapy. For the treatment of complicated vari
cella in immunocompetent patients, only open label studies are available. A
mong 56 patients receiving early acyclovir, only 2 deaths are observed. Pap
ers on immunodepressed patients often associated varicella and tester. The
two randomized studies include only 14 varicella among 66 patients. The lar
gest retrospective study includes 57 varicella among 113 patients, Treatmen
ts used include acyclovir, sorivudine, adenine arabinoside or varicella tes
ter immune globulins. Only 12 deaths are observed among 113 treated varicel
la. Analyses of experts recommendations shows a consensus for treating comp
licated varicella and conflicting opinions for the treatment of uncomplicat
ed varicella in the immunocompetent adult. The treatment of uncomplicated v
aricella in the immunocompetent adult shows a modest benefit. Treatment of
complicated varicella or of the immunocompromised host is highly beneficial
, however, comparative studies of a sufficient power are needed to evaluate
the efficacy of treatment on varicella mortality.